PAD (peripheral arterial disease) device co closes $25m series B:
This article was originally published in Clinica
Pathway Medical Technologies, the Redmond, Washington-based developer of the Pathway Atherectomy system for treating peripheral arterial disease (PAD), welcomed two new shareholders this week, following the completion of a $25m series B financing. HLM Venture Partners (Boston, Massachusetts) led the round and Latterell Venture Partners (San Francisco, California) participated together with existing investors ABN AMRO Capital Lifesciences, Giza Ventures and Oxford Bioscience.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.